Skip to main content
SpringerLink
Log in

Rezidivrisiko senken und das Überleben verlängern

Neoadjuvante Therapie des nicht-kleinzelligen Lungenkarzinoms

  • CME Fortbildung
  • Published:
Pneumo News Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

© A. Gillissen

2

Mit freundlicher Genehmigung aus [30].

Literatur

  1. Dziedzic DA, Rudzinski P, Langfort R et al. Risk Factors for Local and Distant Recurrence After Surgical Treatment in Patients With Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2016;17:e157-e167

  2. Crosbie PAJ, Shah R, Krysiak P et al. Circulating Tumor Cells Detected in the Tumor-Draining Pulmonary Vein Are Associated with Disease Recurrence after Surgical Resection of NSCLC. J Thorac Oncol. 2016;11:1793-7

  3. NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383:1561-71

  4. Burdett S, Stewart LA, Rydzewska L. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol. 2006;1:611-21

  5. Burdett SS, Stewart LA, Rydzewska L. Chemotherapy and surgery versus surgery alone in non-small cell lung cancer. Cochrane Database Syst Rev. 2007;CD006157

  6. Zhang Y, Hu X, Liu D et al. Effectiveness of neoadjuvant chemotherapy on the survival outcomes of patients with resectable non-small-cell lung cancer: A meta-analysis of randomized controlled trials. Surg Oncol. 2021;38:101590

  7. Travis WD, Dacic S, Wistuba I et al. IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. J Thorac Oncol. 2020;15:709-40

  8. Pataer A, Kalhor N, Correa AM et al. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2012;7:825-32

  9. Stein JE, Lipson EJ, Cottrell TR et al. Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade. Clin Cancer Res. 2020;26:545-51

  10. de Scordilli M, Michelotti A, Bertoli E et al. Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing Trials. Int J Mol Sci. 2022;23:7222

  11. Lee J, Chaft J, Nicholas A et al. PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: LCMC3 Trial Primary Analysis. J Thorac Oncol. 2021;16:S59-S61

  12. Shu CA, Gainor JF, Awad MM et al. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21:786-95

  13. Forde PM, Chaft JE, Smith KN et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. 2018;378:1976-86

  14. Bott MJ, Yang SC, Park BJ et al. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2019;158:269-76

  15. Cascone T, William WN, Weissferdt A et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021;27:504-14

  16. Sepesi B, Zhou N, William WN et al. Surgical outcomes after nivolumab or nivolumab with ipilimumab treatment in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2022;164(5):1327-37

  17. Reuss JE, Anagnostou V, Cottrell TR et al. Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. J Immunother Cancer. 2020;8:e001282

  18. Leal TA, Ramalingam SS. Neoadjuvant therapy gains FDA approval in non-small cell lung cancer. Cell Rep Med. 2022;3:100691

  19. Eichhorn F, Klotz LV, Bischoff H et al. Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial. BMC Cancer. 2019;19:413

  20. Shen D, Wang J, Wu J et al. Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB-IIIB resectable lung squamous cell carcinoma. J Thorac Dis. 2021;13:1760-8

  21. Lemmon CA, Videtic GMM, Murthy S et al. A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC. JTO Clin Res Rep. 2022;3:100359

  22. Altorki NK, McGraw TE, Borczuk AC et al. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. Lancet Oncol. 2021;22:824-35

  23. Rothschild SI, Zippelius A, Eboulet EI et al. SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial. J Clin Oncol. 2021;39:2872-80

  24. Gao S, Li N, Gao S et al. Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. J Thorac Oncol. 2020;15:816-26

  25. Zhang P, Dai J, Sun F et al. Neoadjuvant Sintilimab and Chemotherapy for Resectable Stage IIIA Non-Small Cell Lung Cancer. Ann Thorac Surg. 2022;114:949-58

  26. Shi Y, Au JS-K, Thongprasert S et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9:154-62

  27. Chen D, Jin Z, Zhang J et al. Efficacy and Safety of Neoadjuvant Targeted Therapy vs. Neoadjuvant Chemotherapy for Stage IIIA EGFR-Mutant Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Front Surg. 2021;8:715318

  28. Lv C, Ma Y, Feng Q et al. Does neoadjuvant targeted therapy provide an opportunity for resectable EGFR-mutant lung cancer: a real-world retrospective study. J Thorac Dis. 2020;12:5324-35

  29. Bao Y, Gu C, Xie H et al. Comprehensive study of neoadjuvant targeted therapy for resectable non-small cell lung cancer. Ann Transl Med. 2021;9:493

  30. Kang J, Zhang C, Zhong W-Z. Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art. Cancer Commun. 2021;41:287-302

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik III, Kreiskliniken Reutlingen, Steinenbergstraße 31, 72764, Reutlingen, Deutschland

    Adrian Gillissen

  2. Klinik für Innere Medizin II, Universitätsklinikum Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Deutschland

    Cornelia Kropf-Sanchen

Authors
  1. Adrian Gillissen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cornelia Kropf-Sanchen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adrian Gillissen.

Ethics declarations

Der Autor und die Autorin erklären erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen. Sie legen folgende potenzielle Interessenkonflikte offen: keine.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags durch zwei unabhängige Gutachten bestätigt wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung.

Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gillissen, A., Kropf-Sanchen, C. Neoadjuvante Therapie des nicht-kleinzelligen Lungenkarzinoms. Pneumo News 15, 32–39 (2023). https://doi.org/10.1007/s15033-022-3448-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15033-022-3448-2

Search

Navigation